

Mobilizing Oxygen Transforming Lives

Industry: Bio-Pharma
Injectable Therapeutics

Initial Target Indication

- Glioblastoma (GBM, Brain Cancer)
- Stroke
- Acute Respiratory Distress Syndrome (ARDS)

Management

- **Evan Unger, M.D.:** Co-founder & Exec. Chair
- **Rong Wang, CFA:** President and CEO
- **Jenny Johnson, PhD:** Co-founder and CSO

Board of Directors

- **Jon Saxe:** Former head of BD, Roche
- **Richard Carmona:** 17th Surgeon General of US
- **Marvin Slepian:** Regents' Professor, University of Arizona

Advisory Board

- **Robert King:** Public company Chief Development Officer
- **Katy Peters:** President, Clinical Neurological Society of America
- **Ferdinand Hui:** Chief, Neurointerventional surgery, Queen's Medical Center; Stroke KOL

Funding to Date

- **\$10.4M** Series A
- **\$7M** Convertible Note
- **\$13.5M** non-dilutive
- **\$4M** additional grants applied
- **>\$6M** management sweat equity

Seeking Funds

- **A new \$7M Round (\$3M 1st Tranche)**
- **3 trials completion:**
 - o GBM Phase IIb
 - o Stroke Phase IIb
 - o ARDS Phase Ib
 - o Non-dilutive covers 60% needs

Executive Summary:

Lack of Oxygen (Hypoxia) is a root cause for treatment resistance, mortality, and morbidity for fatal diseases such as cancer, stroke, and acute respiratory distress syndrome (ARDS). Our product, NanO₂TM, is the first-in-class therapeutic to reverse tissue hypoxia. Consisting of extremely small oxygen (O₂) carrying nanodroplets that travel with blood, NanO₂ is administered via simple IV and becomes nanobubbles in the body, delivering ~1000x more O₂ than liquids of the same class. Once encountering hypoxic tissue, it partitions into the tissue. It is not metabolized and exits the body via exhalation. The product originated from similar material in a diagnostic application. Thus, we refer to safety data in ~ 2000 patients.




GBM (the deadliest brain cancer) is a **rare** and **fatal** disease without good alternatives. **One in 4** people suffer stroke in life time and it is the most expensive category in the healthcare system. Our Phase IIa GBM trial resulted in 5 months improvement in overall survival and ~40% improvement in progression free survival. Our Phase IIa Stroke trial resulted in significant improvement of functional independence. We currently treat patients in a Phase IIb GBM trial, and in late 2024, we will enter into a Phase IIb stroke trial and a Phase Ib ARDS trial.

NuvOx has 15 strong team members, seasoned management, and a full infrastructure including an ISO 7/ISO 5 cGMP facility.

Market opportunity/Unmet Need:

- **Immediate Markets:** GBM is an entry point to the vast US oncology market of \$65Bn. Stroke affects ~800,000 patients in the US, the majority in ischemic stroke. United States stroke diagnostic and therapeutic market size was valued at \$5.4Bn in 2023 and is projected to grow to \$11.6Bn by 2032. ARDS affects >200,000 patients alone in the US. A small penetration of these markets will result in a **massive ultimate revenue**.
- **Future markets:** A true platform, we will expand into traumatic brain injury (TBI), Cardiac Arrest, and others.

Product Development, Milestone, and Regulatory Strategy:

Clinical Programs	Completed Trial	Current Trial	# of Patients	Grant Funding	Launch Date	'24 YE Milestone	Projected Completion	Next Phase Development
Glioblastoma (Orphan Drug)	Phase IIa	Phase IIb	87		Mid '23	50% of enrollment	End '25	Pivotal trial and/or expedited approval, entry to vast oncology market
Stroke	Phase IIa	Phase IIb	150		End '24	Launching 1st site	Mid '26	Pivotal trial
Respiratory (ARDS)		Phase Ib	18		Q3 '24	60% of enrollment	Mid '25	Phase II, already allowed in Canada
Funded By	Previous Rounds						Next Round	Major Capital Event

Preclinical programs include Immuno-Oncology (\$1.5M DoD grant), Cardiac Arrest, TBI, Sickle Cell (inactive IND), and Hemorrhagic Shock.

Intellectual Property

- 11 patent families; 11 issued US patents + Foreign equivalent (all major markets).
- Both composition-of-matter and method-of-use.

Contact - Ms. Rong Wang | rwang@nuvoxpharma.com